Steady state telithromycin pharmacokinetics and pharmacodynamic in adult patients with mild-moderate acute exacerbation of chronic obstructive pulmonary disease treated with a standard oral dose 800 mg od for 5 days.

Trial Profile

Steady state telithromycin pharmacokinetics and pharmacodynamic in adult patients with mild-moderate acute exacerbation of chronic obstructive pulmonary disease treated with a standard oral dose 800 mg od for 5 days.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2011

At a glance

  • Drugs Telithromycin (Primary)
  • Indications Bacterial infections; Chronic bronchitis; Chronic obstructive pulmonary disease; Respiratory tract infections
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms TELI-AECOPD
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top